

Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

<https://marketpublishers.com/r/G1D650A37C0EN.html>

Date: March 2018

Pages: 280

Price: US\$ 2,400.00 (Single User License)

ID: G1D650A37C0EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024” Report Highlights:

Price & Dosage Analysis of Commercially Available Drugs

Patent, Price & Dosage Analysis of Recently Approved Drugs

Market Analysis of Diffuse Large B Cell Lymphoma

Market Sales Opportunity till 2024

Global Diffuse Large B Cell Lymphoma Clinical Pipeline: 84 Drugs

Marketed Global Diffuse Large B Cell Lymphoma Clinical Insight

Hematological Cancers are the most fatal types of cancer as they affect the blood cells which can directly or indirectly affect every organ of the body. Lymphoma is a type of blood cancer in which B-lymphocytes of the white blood cells are affected. Non-Hodgkin Lymphoma being a major class of Lymphoma is segmented into several specific types of cancers amongst which Diffuse Large B-cell Lymphoma is the most common sub-type affecting a major population globally.

As Diffuse Large B-cell Lymphoma is rare hematological malignancy, due to small

target patient-base, very few specific therapies were developed for its treatment. However, in the last decade, with the arrival of anti-CD20 monoclonal antibody Rituxan which gained a huge market success due to high market demand fueled the market for diffuse large b-cell lymphoma. Soon after that, pharmaceutical industry recognized the potential of this segment of the market considering that highly unmet medical needs and increasing demand of effective therapy will drive the market in this segment.

With the rise in incidence and mortality rates due to Diffuse Large B-cell lymphoma, researchers and pharmaceutical industry have shifted their focus to develop unique targeted therapies for this type of cancer. Recently, pharmaceutical industry has provided a wide range of targeted drugs for Diffuse Large B-cell Lymphoma. This scenario clearly indicates that diffuse large b-cell lymphoma market has grown exponentially in past decade.

Recently, conventional treatment options including cytotoxic chemotherapeutics including doxorubicin; cyclophosphamide; vincristine and prednisone were introduced in the market as combination therapies along with the immunotherapeutic Rituxan for treating Diffuse Large B-cell Lymphoma. Rituxan has gained much importance in the market both as monotherapy and a significant component of combination therapy by enhancing the survival of 41% patients to 65% patients with diffuse large b-cell lymphoma. However, in recent studies, few researchers have demonstrated that patients have developed resistance for Rituxan combination therapy over a long period of time.

Additionally, patent expiration of the popular drug Rituxan has induced the development and arrival of several Rituxan Biosimilars in the market which is again boosting the Diffuse Large B-cell Lymphoma market. Europe currently has nearly 5 and US has 3 marketed biosimilars of Rituxan. In spite of the commercialization of biosimilars, the sales of Rituxan are still increasing. Rituxan has successfully collected nearly US\$ 32 Billion revenues cumulatively in past 3 years.

More recently Yescarta which is the second CAR-T cell therapy to be approved by US FDA has entered the market. Another recently approved therapy is Ibrutinib which is an advanced targeted therapy has been commercialized. Both of these therapies have a great potential to generate high revenues for the pharmaceutical companies due to high efficacy of these products. Nonetheless, the huge market acceptance of Rituxan encourages the researchers and pharmaceutical industry to explore new opportunities in the drug which can further enhance Rituxan market at a higher rate and contribute to

the growth of diffuse large b-cell lymphoma market.

Rituxan has been approved as a combination therapy called Rituxan Hycela. In this therapy Rituxan has been combined with an enzymatic therapy called Hyaluronidase. Such approaches by using popular drugs aids in securing the market place of a popular drug and further enhancing the overall Diffuse Large B-cell lymphoma market. The diffuse large b-cell lymphoma market has experienced a huge progress in past four-five years and is expected to grow in the coming future.

The diffuse large-B cell lymphoma Market has shown an impressive growth in the market size with continuous approvals of several advanced therapies including immunotherapy, CAR-T cell therapy and targeted therapy. Development of such advanced therapies is indeed a result of huge investments and funding from public as well as private sectors and continuous efforts of educational institutes for high quality research and innovations. Additionally, increasing incidence of the disease has also fuelled the diffuse large b-cell lymphoma market significantly. This scenario clearly indicates that global diffuse large b-cell lymphoma market acquires a major portion of modern cancer therapy market with a wide variety of advanced therapies indicated for this disease.

As diffuse large b-cell lymphoma occurs commonly in older population, the market can be segmented into regions with high population above 65 years. Thus the diffuse large b-cell lymphoma market has higher potential in North America due to large ageing population and several active ongoing research studies in this region. Europe is dominant in terms of availability of products in the market including Rituxan biosimilars and other unique therapeutics for treating diffuse large b-cell lymphoma. Furthermore, China and Japan also show highly opportunistic diffuse large b-cell lymphoma market.

We have analyzed a wide variety of aspects related to Diffuse Large B-Cell Lymphoma Market including the funding, investment, ongoing researches and development and commercialization of new therapies for treating Diffuse Large B-cell Lymphoma. Additionally, our research also includes the data about costs, consumer-base and commercial status of marketed & potential Therapeutics for treating Diffuse Large B-cell Lymphoma by collecting information from multiple sources. Constitutively, the report interprets the real facts and figures suggesting a positive market outlook of diffuse large B-Cell Lymphoma Market.

Contents

1. DIFFUSE LARGE B CELL LYMPHOMA

- 1.1 Introduction
- 1.2 Classification of Diffuse Large B Cell Lymphoma

2. MOLECULAR EVENTS INVOLVED IN DIFFUSE LARGE B CELL LYMPHOMA PATHOGENESIS

- 2.1 BCL6
- 2.2 BCL-2
- 2.3 MYC Gene
- 2.4 P53

3. MANAGEMENT APPROACHES FOR DIFFUSE LARGE B CELL LYMPHOMA

- 3.1 Diagnostic Approaches
 - 3.1.1 Bone Marrow Biopsy Method
 - 3.1.2 Positron Emission Tomography (PET)
- 3.2 Therapeutic Approaches
- 3.3 Radiation Therapy

4. PRICE & DOSAGE ANALYSIS OF COMMERCIALY AVAILABLE DRUGS

- 4.1 Rituxan
- 4.2 Cyclophosphamide
- 4.3 Doxorubicin
- 4.4 Vincristine
- 4.5 Prednisone

5. PATENT, PRICE & DOSAGE ANALYSIS OF RECENTLY APPROVED DRUGS

- 5.1 Axicabtagene Ciloleuceel (Yescarta)
- 5.2 Ibrutinib (Imbruvica)
- 5.3 Hyaluronidase

6. MARKET ANALYSIS OF DIFFUSE LARGE B CELL LYMPHOMA

6.1 Introduction to Lymphoma Disease

6.1.1 Market Exploration of Hodgkin Lymphoma

6.1.2 Market Size of Non-Hodgkin Lymphoma

6.2 Market Outlook of Diffuse Large B Cell Lymphoma

7. CURRENT TRENDS IN TREATMENT OF DIFFUSE LARGE B CELL LYMPHOMA

8. MARKET DYNAMICS OF DIFFUSE LARGE B CELL LYMPHOMA

8.1 Favorable Market Parameters

8.2 Commercialization Challenges

9. FUTURE PERSPECTIVE OF DIFFUSE LARGE B CELL LYMPHOMA

10. GLOBAL DIFFUSE LARGE B CELL LYMPHOMA CLINICAL PIPELINE BY COMPANY & PHASE

10.1 Global Diffuse large B Cell Lymphoma Pipeline Overview

10.2 Research

10.3 Preclinical

10.4 Clinical

10.5 Phase-I

10.6 Phase-I/II

10.7 Phase-II

10.8 Phase-III

10.9 Registered

10.10 Preregistration

11. MARKETED GLOBAL DIFFUSE LARGE B CELL LYMPHOMA CLINICAL INSIGHT BY COMPANY

11.1 Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)

11.2 Rituximab Biosimilar (Novex)

11.3 Rituximab Biosimilar (Maball)

12. COMPETITIVE LANDSCAPE

12.1 AbbVie

12.2 Arrien Pharmaceuticals

12.3 Aptose Biosciences

12.4 BeiGene

12.5 Celltrion

12.6 CTI BioPharma

12.7 Erytech Pharma

12.8 Hetero Drugs

12.9 Karyopharm Therapeutics

12.10 mAbxience

12.11 PIQUR Therapeutics

12.12 Philogen S.p.A.

12.13 Roche

12.14 Seattle Genetics

12.15 TG Therapeutics

List Of Figures

LIST OF FIGURES

- Figure 1-1: Representation of T Lymphocytes & B Lymphocytes Cases of Non-Hodgkin Lymphoma (%)
- Figure 1-2: Categorization of Diffuse Large B cell Lymphoma
- Figure 2-1: Role of BCL6 Gene B Cell Differentiation for the Development of Diffuse Large B cell Lymphoma
- Figure 2-2: Pathogenesis of Diffuse Large B cell Lymphoma by BCL-2 Oncogene
- Figure 2-3: Involvement of MYC Gene in the Proliferation of Diffuse Large B cell Lymphoma
- Figure 3-1: Diagnostic Methods of Diffuse Large B cell Lymphoma
- Figure 4-1: Rituxan - Patent Approval Year & Expiration Year
- Figure 4-2: Rituxan – Dose Schedule in a Cycle (by Number), 2018
- Figure 4-3: Rituxan – Availability in Market by Vial Concentration (mg), 2018
- Figure 4-4: Global - Rituxan Intravenous Solution Price by Concentration (10mg/mL) (US\$/Unit), 2018
- Figure 4-5: Rituxan – Price Analysis by Concentration (US\$), 2018
- Figure 4-6: Rituxan - Treatment Cost Analysis for Intravenous Route of Administration (US\$), 2018
- Figure 4-7: Global - Rituxan Sales (US\$ Billion), 2015-2017
- Figure 4-8: Cyclophosphamide - Available Intravenous Powder Concentration (mg/vial), 2018
- Figure 4-9: Cyclophosphamide - Available Capsule Concentration (mg/vial), 2018
- Figure 4-10: Cyclophosphamide – Dosage Analysis in Initial Treatment Course (mg/kg), 2018
- Figure 4-11: Cyclophosphamide – Maximum Dose in Treatment Course (mg/kg), 2018
- Figure 4-12: Cyclophosphamide – Dosage Analysis for Diffuse Large B- Cell Lymphoma (mg/m²/Day), 2018
- Figure 4-13: Cyclophosphamide - Intravenous Powder Price Analysis by Concentration (mg), 2018
- Figure 4-14: Cyclophosphamide - Capsule Price Analysis by Concentration (mg), 2018
- Figure 4-15: Doxorubicin - Available Intravenous Powder Concentration (mg), 2018
- Figure 4-16: Doxorubicin – Availability in Market by Vial Quantity (2mg/ml), 2018
- Figure 4-17: Doxorubicin – Initial Dosage (mg/m²/Dose)
- Figure 4-18: Doxorubicin – Maximum Dosage (mg/m²/Dose)
- Figure 4-19: Doxorubicin – Duration of Treatment Cycle (Number of Days)
- Figure 4-20: Doxorubicin - Intravenous Powder Price Analysis by Concentration (US\$),

2018

Figure 4-21: Doxorubicin - Intravenous Solution Price Analysis by Concentration (US\$), 2018

Figure 4-22: Vincristine – Dosage Analysis (mg/ml/Week)

Figure 4-23: Vincristine – Availability in Market by Vial Quantity (ml), 2018

Figure 4-24: Vincristine - Intravenous Solution Price Analysis by Concentration (US\$), 2018

Figure 4-25: Prednisone – Available Oral Solution by Concentration (ml), 2018

Figure 4-26: Prednisone - Available Oral Tablet by Concentrations (mg), 2018

Figure 4-27: Prednisone - Oral Solution Price Analysis by Concentration (US\$), 2018

Figure 4-28: Prednisone - Oral Tablet Cost Price Analysis (US\$/100 Tablets), 2018

Figure 5-1: Yescarta – Patent Approval Year in US & Estimate Treatment Cost (US\$)

Figure 5-2: Information of Yescarta Drug among the Population (%)

Figure 5-3: Imbruvica – US Patent Approval Year & Patent Expiration Year

Figure 5-4: Imbruvica - 140mg Capsule Price Analysis (US\$/Packet), 2018

Figure 5-5: Imbruvica - Treatment Cost Analysis (US\$), 2018

Figure 5-6: Imbruvica – Clinical Efficacy by Survival Rate & Survival Response (%), 2018

Figure 5-7: Imbruvica - Global Sales (US\$ Billion), 2015 - 2017

Figure 5-8: Rituxan Hycela – Availability by Concentration (ml), 2018

Figure 5-9: Rituxan Hycela – Cell Units in Vial (by Number), 2018

Figure 5-10: Rituxan Hycela – Dosage in CHOP Therapy (mg/Cell Units), 2018

Figure 5-11: Rituxan Hycela – Price Analysis by Concentration (US\$/Unit), 2018

Figure 5-12: Rituxan Hycela – Vial Price Analysis (US\$), 2018

Figure 6-1: Global - Estimated Number of All New Annual Cancer Cases (%), 2018

Figure 6-2: Estimated New Annual Cases of Blood Cancers, 2018 (%)

Figure 6-3: Distribution of Types of Lymphoma (%)

Figure 6-4: Global - Hodgkin Lymphoma Market Opportunity (US\$ Billion), 2017-2024

Figure 6-5: Global- Non-Hodgkin Lymphoma Market Growth Estimation (US\$ Billion), 2017-2024

Figure 6-6: Classification of Subtypes of Non-Hodgkin Lymphoma Market (%)

Figure 6-7: Global - Patients Affected by Issues Before, During & After the Treatment (%), 2016

Figure 6-8: Barriers to Adequate Treatment Approach of Diffuse Large B cell Lymphoma (%), 2016

Figure 8-1: Favorable Factors for the Growth of Diffuse Large B cell Lymphoma Market

Figure 8-2: Challenges to the Growth of Diffuse Large B cell Lymphoma Market

Figure 10-1: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (%), 2018 till 2024

Figure 10-2: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 10-3: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (%), 2018 till 2024

Figure 10-4: Global Diffuse Large B Cell Lymphoma Clinical Pipeline by Phase (Number), 2018 till 2024

List Of Tables

LIST OF TABLES

Table 3-1: Diagnostic Positron Emission Tomography Scan by Histology

Table 3-2: Standard Regimen of R-CHOP Chemotherapy plus Monoclonal Antibody for 6 Cycles

Table 5-1: Response Rate of Recipients who Received Yescarta Drug in Clinical Trials (%)

Table 5-2: Cost Effective Analysis of Imbruvica Drug

Table 5-3: Response Effective Analysis of Rituxan Hycela Injection in Clinical Trials

Table 9-1: Ongoing PD-1 Inhibitors Clinical Trials Related with Diffuse Large B cell Lymphoma

I would like to order

Product name: Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

Product link: <https://marketpublishers.com/r/G1D650A37C0EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1D650A37C0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

